Moderna is trading 8.31% higher at $213.38, with Nasdaq-100 inclusion-related buying the clearest catalyst. - Nasdaq confirmed the addition, effective before the October 9 open; index-tracking funds may need to buy shares, creating potential technical demand. - Moderna's mFlusiva launch on October 8 is recent company news, but available coverage does not connect it directly to the move. - Biotech is weaker, so sector performance does not explain the rise.